The bilirubin-displacing capacity of bumetanide in critically ill neonates.
Effects of bumetanide on in vitro bilirubin binding to albumin were studied in pooled sera of critically ill neonates using the hydroxybenzeneazobenzoic acid (HBABA) dye binding method and the horseradish peroxidase assay. Mean HBABA dye binding capacity decreased significantly from 63.75 +/- 5.9% in the absence of drug to 50.8 +/- 6.7% and 44.6 +/- 6.3% with concentrations of 0.25 and 50 micrograms/ml, respectively (p less than 0.005). Bumetanide caused an increase in unbound bilirubin concentration at drug concentrations of 0.5-50 micrograms/ml. Bumetanide is a potent displacer of bilirubin and should be used with caution in jaundiced neonates.
Walker
P C
PC
Wayne State University College of Pharmacy and Allied Health Professions, Detroit, Mich.
Shankaran
S
S
D001391:Azo Compounds; D001663:Bilirubin / Q000378:metabolism*; D001667:Binding, Competitive; D002034:Bumetanide / Q000494:pharmacology*; D004232:Diuretics / Q000494:pharmacology*; D006735:Horseradish Peroxidase; D006801:Humans; D007231:Infant, Newborn
D001391:Azo Compounds; D004232:Diuretics; D002034:Bumetanide; C001413:HABA; D006735:Horseradish Peroxidase; D001663:Bilirubin